March 19, 2024

Covid-19: How Will It Affect Fall Sports

Covid-19 Pandemic Affecting Fall Sports

The coronavirus pandemic has changed how Americans do business – it has also affected how we play.

Many organized sports took a hiatus during the spring and summer as players, organizers, public health officials, and fans looked for ways to play safely, and are now trying to squeeze out a fall schedule. For example, soccer is a patchwork of canceled games, limited practices, and normal seasons… at least for now, as COVID-19 flare-ups may dash the dreams of players of all ages.

The decision to play has been especially difficult at the high school level. Most states have canceled high school basketball championships and spring seasons, for example, even before the start of school. Football was a different story, though. Football is a beloved fall tradition and, for pros and amateurs alike, marks the beginning of sports season. The decision whether to nix the fall season has been a controversial and often divisive one – nearly everyone wants football to return, but many wondered how to do it safely.

Twenty-five states had already kicked off their high school football season by September 17, and nine more planned to start their seasons in the fall. By then, a number of states and the District of Columbia said they would push their seasons back to 2021. Colorado had announced they would offer football in both fall and spring. Michigan had reversed their decision twice, moving football from fall to spring on August 14 then moving it back to fall on September 3,2020.

The pandemic has also tripped up recruiting efforts, particularly for high school seniors. High school sport seasons provide athletes with an opportunity to score scholarships that could change the course of their lives. In a typical year, young athletes have several chances to impress college scouts, but 2020 is anything but typical – the pandemic prevents coaches and prospects from traveling to meet in person, and it led to the cancelation of exposure camps normally held in late summer and early autumn.

Fall Sports at the Collegiate Level

On September 22, 2020, the NCAA announced that a number of college sports would hold their 2020 fall championships in the spring of 2021. Sports included are men’s and women’s soccer, men’s and women’s cross-country, women’s volleyball, field hockey, and men’s water polo. They will cap bracket sizes at 75 percent of normal capacity, predetermine championship sites, and reduce the number of preliminary-round sites to support health and safety. While the NCAA has halted most college sports for the fall season, college football goes on. Mid-American Conference (MAC) announced their return on September 25, 2020, which means all 10 Football Bowl Subdivision (FBS) conferences are now competing in the fall. They committed to playing a 6-game conference-only schedule running from November 4th through December 18 or 19, with the MAC championship game. To keep players safe, MAC implemented COVID-19 testing protocols that call for four COVID tests per week, starting October 5. MAC is not allowing general public attendance or tailgating; Conference protocols will guide participation of any Marching Bands, Dance, Cheer and Spirit Squads at football games according to institutional discretion and public health guidance. MAC’s announcement cited the availability of COVID-19 tests and the quick turnaround time of test results across the Conference as leading to the decision to play.

Big Ten recently announced it would start its season on October 24, 2020, prompting 90 teams to attempt playing a full schedule this fall. The ACC, Big 12 and SEC as the Power 5 conferences will also try to play this fall, as will the American, Conference USA and Sun Belt.

Pro Sports During the Pandemic

Professional football is on in full force this fall, with the NFL planning to play a complete schedule. Just one year after celebrating the NFL’s 100th season in grand fashion, this year will feature mostly empty stadiums and canned cheers, officials and coaches in masks, the wearing of tracking devices for contact tracing, daily testing, socially distant meetings, and other protocols to keep fans and players safe. Players who test positive are placed on the reserve/COVID list. On September 26, Atlanta Falcons cornerback A.J. Terrell became the first player to be sidelined after a positive COVID-19 test.

It is hard to know how the pandemic will affect athletes and fans as we move from autumn to winter, but rest assured, the world of sports may never be the same.

FRANK MAGLIOCHETTI

Frank Magliochetti owes his professional success to his expertise in two areas: medicine and finance. After obtaining a BS in pharmacy from Northeastern University, he stayed on to enroll in the Masters of Toxicology program. He later specialized in corporate finance, receiving an MBA from The Sawyer School of Business at Suffolk University. His educational background includes completion of the Advanced Management Program at Harvard Business School and the General Management Program at Stanford Business School. Frank Magliochetti has held senior positions at Baxter International, Kontron Instruments, Haemonetics Corporation, and Sandoz. Since 2000, he has been a managing partner at Parcae Capital, where he focuses on financial restructuring and interim management services for companies in the healthcare, media, and alternative energy industries. Last year, he was appointed chairman of the board at Grace Health Technology, a company providing an enterprise solution for the laboratory environment. Frank is also CEO of ClickStream, ClickStream’s business operations are focused on the development and implementation of WinQuik™, a free to play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuik™ users to have fun, interact and compete against each other in order to win real money and prizes. Twitter at @ClickstreamC and @WinQuikApp.

Frank was appointed Chairman and Chief Executive Officer at Designer Genomics International, Inc. The Company has accumulated a growing body of evidence that highlights a link between alterations in the immune and inflammatory systems and the development of chronic human disease. The Company is visionary and has established itself as a leader in the field of inflammatory and immune genetic DNA and RNA biomarkers that play a causative role in debilitating conditions, such as atherosclerosis/heart disease, diabetes, arthritis, inflammatory bowel disease, post-traumatic stress disorders (PTSD) and cancer.
A proprietary state-of-the art data mining bioinformatics program, called ‘cluster analysis’ will be used to measure disease development susceptibility with potential for earlier diagnosis and intervention. The company is developing a healthcare program based on its proprietary genetic panels that will allow people to be their own healthcare advocate and take an active role in their health status as well as longevity.

This image has an empty alt attribute; its file name is frankmagliochetti_FrankMagliochettiNews.jpg
Mr. Frank Magliochetti MBA
Managing Partner
Parcae Capital

www.parcaecapitalcorp.com
www.frankmagliochetti.com

Sources

https://www.maxpreps.com/news/qiL5GOXkFkyfJ9jwZ8wb-g/where-the-start-of-high-school-sports-stands-in-all-50-states-amid-pandemic.htm

https://www.maxpreps.com/news/ha3S_dWexUOaekUFjBMfkA/high-school-football-kickoff-dates-in-all-50-states.htm

https://www.ncaa.com/live-updates/ncaa/ncaa-sports-news-schedule-changes-coronavirus-updates-all-sports

https://getsomemaction.com/news/2020/9/25/football-maction-is-back.aspx

https://www.nfl.com/news/falcons-cb-a-j-terrell-tests-positive-for-covid-19-placed-on-reserve-list

Covid-19: The Race for a Vaccine Continues

Covid-19: The Race for a Vaccine

The race to save lives has begun. Scientists around the world are speeding to develop a vaccine for COVID-19, a disease that has claimed the lives of more than half a million lives worldwide, and sickened millions of others. Vaccine development usually takes 10 to 15 years, and the long, involved process takes a tremendous amount of public and private involvement. At the current rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections that cause COVID-19 disease, though, the world does not have 10 to 15 years to wait.

COVID-19 Race for a vaccine

On July 18, 2020, the World Health Organization (WHO) reviewed 23 candidate vaccines in clinical evaluation. Many were still in Phase 1 to establish their safety and dosage at the time of the WHO review, while others were in Phase 2 to establish their performance under ideal and controlled performance. As of that mid-July WHO review, three clinical trials had entered Phase 3 for testing on large numbers of people, although one vaccine trial had not yet recruited candidates.

Why Must We Wait So Long?

Most vaccines in development never make it to licensing – in fact, many vaccine candidates never make to clinical evaluation on real humans because they fail to produce the desired immune response in the pre-clinical stages of testing in cell cultures and lab animals.

Regulators set a high bar for vaccination approval and often require years’ worth of safety data because, unlike medicines that treat diseases, vaccines are administered to healthy people to prevent illness. Releasing a vaccine could potentially do more harm than good, so many regulatory bodies set stiff guidelines for approval.

covid-19-race for A CURE

It is not yet clear what data federal regulators would accept as proof that a vaccine is safe and successful in the middle of the pandemic. On June 30, 2020, the U.S. Food and Drug Administration (FDA) said a vaccine must prevent COVID-19 or decrease the severity of illness in at least 50 percent of people who receive the vaccine. The FDA may consider some vaccine candidates for its Accelerated Approval pathway, but that the vaccine candidate must demonstrate an identifiable immune response or other measure that shows it is reasonably likely that the vaccine would provide clinical benefit. Regulators in other nations have not yet announced what they would consider acceptable criteria for approval, which creates a challenge for vaccine makers trying to gain approval.

More Challenges for Vaccine Makers

Vaccine makers also face challenges determining the best way to trigger the immune response. Vaccines typically work by exposing the body to the antigens of a particular pathogen to activate the immune system without causing disease. Made with weakened or inactivated form of the pathogen, these vaccines are often difficult to develop and produce quickly. Because of the urgent nature of the pandemic, researchers are looking for innovating ways to introduce antigens and otherwise activate an immune response to SARS-CoV-2. Four of the 23 vaccine candidates in clinical testing use an approach that involves engineering messenger RNA (mRNA) that tells human cells how to create the antigens themselves.

RACE FOR A VACCINE COVID-19

Moderna is one of those four companies. On July 15, 2020, the biotech company published data from an early-stage trial that shows its vaccine caused patients to generate an immune response by developing antibodies, although it caused some side effects. Supported by the National Institutes of Health, the study showed volunteers who receive the vaccine produced substantially more neutralizing antibodies than do most patients who have recovered from COVID-19. A second injection administered four weeks after the initial vaccination was necessary to produce a dramatic immune response. Vaccine experts were not impressed, however, concerned that the data was long on text and short on proof.

Other research teams, such as University of Oxford/AstraZeneca are using viral vector vaccines to speed up the process. Viral vector vaccines use a harmless virus as a kind of Trojan horse that carries the pathogen’s genetic material into cells in order to trigger an immune response. The team released more information about its coronavirus vaccine candidate, AZD1222, on July 20, 2020.

Developing a COVID-19 vaccine will be one of the most exciting and important events in human history, with the potential to save millions of lives around the world. Join us next month when we review the next leg of the race for a COVID-19 vaccine.

To View Frank Magliochetti Press Releases Please CLICK HERE

Frank Magliochetti owes his professional success to his expertise in two areas: medicine and finance. After obtaining a BS in pharmacy from Northeastern University, he stayed on to enroll in the Masters of Toxicology program. He later specialized in corporate finance, receiving an MBA from The Sawyer School of Business at Suffolk University. His educational background includes completion of the Advanced Management Program at Harvard Business School and the General Management Program at Stanford Business School. Frank Magliochetti has held senior positions at Baxter International, Kontron Instruments, Haemonetics Corporation, and Sandoz. Since 2000, he has been a managing partner at Parcae Capital, where he focuses on financial restructuring and interim management services for companies in the healthcare, media, and alternative energy industries. Last year, he was appointed chairman of the board at Grace Health Technology, a company providing an enterprise solution for the laboratory environment. Most recently; Frank was appointed Chairman and Chief Executive Officer at Designer Genomics International, Inc. The Company has accumulated a growing body of evidence that highlights a link between alterations in the immune and inflammatory systems and the development of chronic human disease. The Company is visionary and has established itself as a leader in the field of inflammatory and immune genetic DNA and RNA biomarkers that play a causative role in debilitating conditions, such as atherosclerosis/heart disease, diabetes, arthritis, inflammatory bowel disease, post-traumatic stress disorders (PTSD) and cancer.
A proprietary state-of-the art data mining bioinformatics program, called ‘cluster analysis’ will be used to measure disease development susceptibility with potential for earlier diagnosis and intervention. The company is developing a healthcare program based on its proprietary genetic panels that will allow people to be their own healthcare advocate and take an active role in their health status as well as longevity.

Mr. Frank Magliochetti MBA
Managing Partner
Parcae Capital

www.parcaecapitalcorp.com
www.frankmagliochetti.com

Sources

https://coronavirus.jhu.edu/map.html

https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation

https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-help-facilitate-timely-development-safe-effective-covid

https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval

https://www.nejm.org/doi/full/10.1056/NEJMoa2022483

https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html